At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BLUE bluebird bio
Market Closed 12-20 16:00:00 EST
8.50
-0.73
-7.91%
盘后8.39
-0.11-1.29%
19:49 EST
High9.80Low7.94Vol900.86K
Open9.20D1 Closing9.23Amplitude20.15%
Mkt Cap82.64MTradable Cap82.26MTotal Shares9.72M
T/O7.81MT/O Rate9.31%Tradable Shares9.68M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Press Release: BLUE MOON METALS CLOSES C$30 MILLION IN EQUITY FINANCING WITH LEAD ORDERS FROM HARTREE PARTNERS, WHEATON PRECIOUS METALS AND LNS, AND SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE TWO NORWEGIAN BROWNFIELD COPPER PROJECTS
Dow Jones  ·  12-20 04:31
Press Release: BLUE MOON METALS CLOSES C$30 MILLION IN EQUITY FINANCING WITH LEAD ORDERS FROM HARTREE PARTNERS, WHEATON PRECIOUS METALS AND LNS, AND SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE TWO NORWEGIAN BROWNFIELD COPPER PROJECTS
Bluebird Bio trading halted, news pending
TIPRANKS  ·  12-13
Bluebird Bio trading halted, news pending
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD
TIPRANKS  ·  12-09
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire  ·  12-09
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Business Wire  ·  12-08
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
BUZZ-U.S. STOCKS ON THE MOVE-Patterson Companies, Hooker Furnishings, Brown-Forman
Reuters  ·  12-05
BUZZ-U.S. STOCKS ON THE MOVE-Patterson Companies, Hooker Furnishings, Brown-Forman
Bluebird bio to Effect 1-for-20 Reverse Stock Split; Shares Fall After Hours
MT Newswires Live  ·  12-05
Bluebird bio to Effect 1-for-20 Reverse Stock Split; Shares Fall After Hours
BRIEF-Bluebird Bio Announces 1-For-20 Reverse Stock Split
Reuters  ·  12-05
BRIEF-Bluebird Bio Announces 1-For-20 Reverse Stock Split
Bluebird Bio announces 1-for-20 reverse stock split
TIPRANKS  ·  12-05
Bluebird Bio announces 1-for-20 reverse stock split
bluebird bio Announces 1-for-20 Reverse Stock Split
THOMSON REUTERS  ·  12-05
bluebird bio Announces 1-for-20 Reverse Stock Split
bluebird bio Announces 1-for-20 Reverse Stock Split
Business Wire  ·  12-05
bluebird bio Announces 1-for-20 Reverse Stock Split
Bluebird Bio participates in CMMI Cell and Gene Therapy Access Model
TIPRANKS  ·  12-04
Bluebird Bio participates in CMMI Cell and Gene Therapy Access Model
CMS enters agreement with Vertex, bluebird to improve access to gene therapies
Reuters  ·  12-04
CMS enters agreement with Vertex, bluebird to improve access to gene therapies
BRIEF-bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Reuters  ·  12-04
BRIEF-bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (Cmmi) Cell and Gene Therapy Access Model
THOMSON REUTERS  ·  12-04
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (Cmmi) Cell and Gene Therapy Access Model
bluebird bio Inc - States Can Opt in to Agreement Until February 28, 2025
THOMSON REUTERS  ·  12-04
bluebird bio Inc - States Can Opt in to Agreement Until February 28, 2025
CMS: 2 Drug Manufacturers With FDA-Approved Gene Therapies for Sickle Cell Disease to Participate in Cell & Gene Therapy Access Model With CMS
THOMSON REUTERS  ·  12-04
CMS: 2 Drug Manufacturers With FDA-Approved Gene Therapies for Sickle Cell Disease to Participate in Cell & Gene Therapy Access Model With CMS
CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026
THOMSON REUTERS  ·  12-04
CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026
THE DISTINCT COBALT BLUE OF SARATOGA® SPRING WATER NOW HAS AN OFFICIAL PANTONE® COLOR: SARATOGA® SIGNATURE BLUE, COLOR 286 C
PR Newswire  ·  12-02
THE DISTINCT COBALT BLUE OF SARATOGA® SPRING WATER NOW HAS AN OFFICIAL PANTONE® COLOR: SARATOGA® SIGNATURE BLUE, COLOR 286 C
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
Benzinga  ·  11-29
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy

Introduction

Company Name.
bluebird bio
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Issue price:
--